Syon Capital’s Summit Therapeutics SMMT Stock Holding History

Syon Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,067	Closed	-$180K	–	655
2024 Q4	$180K	Buy	+10,067	New	+$195K	0.02%	528

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Syon Capital's SMMT Position: Q1 2025 in Review

Syon Capital sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 10,067 shares — an estimated $180K sold.

Syon Capital first reported a position in SMMT in Q4 2024 and held it in 1 quarter. The position peaked at $180K in Q4 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

Syon Capital reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 10,067 Summit Therapeutics shares in Q1 2025, an estimated $180K.
Syon Capital first reported a position in Summit Therapeutics in Q4 2024 and held it in 1 quarter.
Syon Capital's Summit Therapeutics position peaked at $180K in Q4 2024.
212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.